Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 128Esophageal Neoplasms 127Esophageal Squamous Cell Carcinoma 77Adenocarcinoma Of Esophagus 36Pancreatic Neoplasms 30Colorectal Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Neoplasms 21Neoplasm Metastasis 19Ovarian Neoplasms 16Melanoma 12Lung Neoplasms 11Carcinoma, Squamous Cell 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Adenocarcinoma 10Endometrial Neoplasms 9Carcinoma, Renal Cell 9Advanced Gastric Cancer 9Squamous Cell Carcinoma of Head and Neck 8Peritoneal Neoplasms 8Colonic Neoplasms 8Carcinoma, Ovarian Epithelial 8Anus Neoplasms 8Digestive System Neoplasms 7Prostatic Neoplasms 6Cholangiocarcinoma 6Biliary Tract Neoplasms 6Uterine Cervical Neoplasms 5Sarcoma 5

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Esophageal Cancer × Paclitaxel × Gastrointestinal × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡